Climb Bio Inc (CLYM) Financial Statements
Free cash flow over the same period: -$54.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CLYMClimb Bio IncFollow CLYM — free
—
Price chart with a free account
- Market cap
- 585.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | 23.3 | 26.2 | 15.4 | 14.3 | 46.7 | 41.9 | |
| Operating income | -35.7 | -45.1 | -40.3 | -82.0 | -67.9 | -64.8 | |
| Pre-tax income | -47.5 | -45.2 | -35.1 | -73.9 | -59.9 | -57.6 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -47.5 | -45.2 | -35.1 | -73.9 | -59.9 | -57.6 | |
| Diluted EPS ($) | -4.24 | -1.72 | -1.30 | -1.53 | -0.88 | -0.82 | |
| Diluted shares (mn) | 12.3 | 26.3 | 27.0 | 48.2 | 67.8 | — |
USD millions · SEC XBRL
Climb Bio Inc — questions
- What is Climb Bio Inc's net income?
- -$57.6M over the twelve months to 2026-06-30.
- What is Climb Bio Inc's free cash flow?
- -$54.5M over the twelve months to 2026-06-30.
- What are Climb Bio Inc's diluted earnings per share?
- $-0.82 over the twelve months to 2026-06-30.
Every figure on this page comes from Climb Bio Inc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.